How do orphan disease patients live during the pandemic of Omicron variant? A nationwide survey of spinal muscular atrophy patients in China

[1]  L. Zheng,et al.  Impact of National Omicron Outbreak at the end of 2022 on the future outlook of COVID-19 in China , 2023, Emerging microbes & infections.

[2]  Jing-wen Ai,et al.  Geriatric risk and protective factors for serious COVID-19 outcomes among older adults in Shanghai Omicron wave , 2022, Emerging microbes & infections.

[3]  B. Cao,et al.  Protein-based vaccine as the booster dose for adults: evidence and beyond , 2022, The Lancet Infectious Diseases.

[4]  J. Kinge,et al.  Association of COVID-19 Vaccination During Pregnancy With Incidence of SARS-CoV-2 Infection in Infants , 2022, JAMA internal medicine.

[5]  C. Steves,et al.  Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study , 2022, The Lancet.

[6]  T. Burki COVID-19 vaccination in young children , 2022, The Lancet Respiratory Medicine.

[7]  S. Schrag,et al.  Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. , 2022, JAMA.

[8]  N. Sewankambo,et al.  Assessment of Clinical Outcomes Among Children and Adolescents Hospitalized With COVID-19 in 6 Sub-Saharan African Countries , 2022, JAMA pediatrics.

[9]  Suresh Kumar,et al.  Omicron and Delta variant of SARS‐CoV‐2: A comparative computational study of spike protein , 2021, Journal of medical virology.

[10]  L. Giacomelli,et al.  Effect of the COVID-19 Pandemic on Children With SMA Receiving Nusinersen: What Is Missed and What Is Gained? , 2021, Frontiers in Neurology.

[11]  C. Ortez,et al.  COVID-19 in children with neuromuscular disorders , 2021, Journal of Neurology.

[12]  W. Wu,et al.  Bioinformatic analysis of SMN1–ACE/ACE2 interactions hinted at a potential protective effect of spinal muscular atrophy against COVID-19-induced lung injury , 2020, Briefings Bioinform..

[13]  M. Temsah,et al.  COVID-19 infection prevalence in pediatric population: Etiology, clinical presentation, and outcome , 2020, Journal of Infection and Public Health.

[14]  R. Finkel,et al.  Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study , 2020, Neurology.

[15]  R. Finkel,et al.  Spinal muscular atrophy — insights and challenges in the treatment era , 2020, Nature Reviews Neurology.

[16]  M. C. Jaklevic Oral Drug Approved for Spinal Muscular Atrophy. , 2020, JAMA.

[17]  Y. Péréon,et al.  Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network , 2020, Revue Neurologique.

[18]  W. Hugentobler,et al.  Seasonality of Respiratory Viral Infections. , 2020, Annual review of virology.

[19]  V. Prasad Nusinersen for Spinal Muscular Atrophy: Are We Paying Too Much for Too Little? , 2017, JAMA pediatrics.

[20]  Hanns Lochmüller,et al.  Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy – a literature review , 2017, Orphanet Journal of Rare Diseases.